CD274 and cancer: Furthermore, efficacy of ICB is correlated with neoantigen burden for a variety of cancers (Yarchoan et al., 2017; Snyder et al., 2014; Carbone et al., 2017; Rizvi et al., 2015a; Galsky et al., 2017; McGranahan et al., 2016), and tumor mutational burden (TMB) may be a better predictor of ICB response than PD-L1-positive staining in some instances (Hellmann et al., 2018).